Ashish Saxena, MD, PhD Discusses Immunotherapy Drugs Effect on OS in Lung Cancer

Ashish Saxena, MD, PhD, from Weill Cornell Medicine, discussed how neoadjuvant and adjuvant immunotherapy may lead to an increase in overall survival of patients with lung cancer at the Annual New York Lung Cancers Symposium^®.

Transcription:
So, I think we’re most excited about moving the immunotherapy drugs to earlier lines of therapy, and sort of increasing the chances of cure from lung cancer. And so, I’m excited to see the studies with, you know, neoadjuvant immunotherapy and adjuvant immunotherapy and how they may play out in terms of increasing the overall survival of patients.